Injectable deferoxamine nanoparticles loaded chitosan-hyaluronic acid coacervate hydrogel for therapeutic angiogenesis

Colloids Surf B Biointerfaces. 2018 Jan 1:161:129-138. doi: 10.1016/j.colsurfb.2017.10.033. Epub 2017 Oct 12.

Abstract

In this study, an injectable chitosan-hyaluronic acid (CS-HA) based hydrogel was designed incorporating pro-angiogenic molecule, deferoxamine loaded PLGA nanoparticles (DFO NPs), for enhancing angiogenesis. DFO-NPs were prepared by double emulsion solvent diffusion technique and characterized for their physicochemical properties. The DLS and SEM analysis showed an average particle size of 220±71nm with spherical morphology and the encapsulation efficiency was found to be 30±5%. An ECM mimicking chitosan-hyaluronic acid (CS-HA) coacervate hydrogel was prepared. Both free DFO and DFO NPs were entrapped into the prepared CS-HA composite hydrogel. The hydrogels were characterized by SEM, FTIR and Rheology. Addition of DFO NPs did not affect the injectablility and flowability of developed hydrogels. In vitro DFO release from the prepared composite hydrogels showed controlled release over a period of 10days. Both the hydrogel systems showed excellent cyto-compatability and good cell proliferation for rASCs as well as HUVECs. The DFO and DFO NPs loaded composite hydrogels revealed effective tube formation in comparison with control hydrogels without DFO and DFO NPs. The in vivo angiogenic evaluation of the free DFO and DFO NPs (0.025%w/w) loaded composite hydrogels were studied by injecting the developed hydrogel subcutaneously into mice for 2-4 weeks. The DFO NPs loaded composite hydrogel had enhanced neovascularization when compared to control gels. Thus, the developed DFO NPs loaded composite hydrogel could potentially be used for therapeutic angiogenesis.

Keywords: Angiogenesis; Chitosan; Coacervate hydrogel; Deferoxamine; Hyaluronic acid; Injectable hydrogel; Neo-vascularization.

MeSH terms

  • Animals
  • Cells, Cultured
  • Chitosan / chemistry*
  • Deferoxamine / administration & dosage*
  • Deferoxamine / chemistry
  • Deferoxamine / pharmacokinetics
  • Delayed-Action Preparations / administration & dosage
  • Delayed-Action Preparations / chemistry
  • Delayed-Action Preparations / pharmacokinetics
  • Drug Liberation
  • Human Umbilical Vein Endothelial Cells / cytology
  • Human Umbilical Vein Endothelial Cells / drug effects
  • Human Umbilical Vein Endothelial Cells / physiology
  • Humans
  • Hyaluronic Acid / chemistry*
  • Hydrogel, Polyethylene Glycol Dimethacrylate / chemistry*
  • Injections
  • Lactic Acid / chemistry
  • Mice, Inbred BALB C
  • Nanoparticles / administration & dosage*
  • Nanoparticles / chemistry
  • Neovascularization, Physiologic / drug effects*
  • Particle Size
  • Polyglycolic Acid / chemistry
  • Polylactic Acid-Polyglycolic Acid Copolymer

Substances

  • Delayed-Action Preparations
  • Polylactic Acid-Polyglycolic Acid Copolymer
  • Hydrogel, Polyethylene Glycol Dimethacrylate
  • Polyglycolic Acid
  • Lactic Acid
  • Hyaluronic Acid
  • Chitosan
  • Deferoxamine